drugset / Trial / NCT06951971
Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
NaSingle-groupOpen-labelTreatment
Summary
This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.
Timeline
- Start
- 2025-06-01
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emapalumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Emapalumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 30 mg | Oral |